0RAR.LSE Stratec SE
- Market cap
- EUR 220M
- P/E
- 7.5x
- P/B
- -
- ROE
- 2.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0RAR.LSE undervalued?
Graham numberThe Graham number of Stratec SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stratec SE fundamental analysis
No fundamental analysis for Stratec SE yet.
Stratec SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name …
Full company profileStratec SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stratec SE annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 185M | 207M | 188M | 214M | 250M | 287M | 275M | 262M | 258M | 251M | 225M |
| Gross Profit | 61.6M | 64.7M | 53.5M | 54.0M | 69.0M | 87.7M | 79.5M | 64.8M | 76.4M | 64.2M | 50.9M |
| Operating Income | 24.7M | 24.3M | 14.3M | 19.0M | 32.5M | 49.6M | 42.0M | 22.9M | 25.7M | 8.59M | 7.25M |
| EBITDA | 35.1M | 40.9M | 34.9M | 36.1M | 52.6M | 65.4M | 57.5M | 43.3M | 47.6M | 27.2M | 25.3M |
| Net Income | 19.5M | 25.6M | 8.97M | 16.1M | 29.2M | 40.0M | 29.2M | 13.1M | 16.0M | -242K | 4.90M |
| EPS | 1.63 | 2.14 | 0.75 | 1.33 | 2.40 | 3.28 | 2.40 | 1.07 | 1.32 | -0.02 | 0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 261M | 269M | 284M | 310M | 342M | 378M | 408M | 471M | 445M | 443M | 411M |
| Total Liabilities | 119M | 111M | 132M | 151M | 170M | 172M | 183M | 246M | 203M | 206M | 172M |
| Shareholders' Equity | 142M | 158M | 152M | 159M | 173M | 206M | 225M | 233M | 243M | 237M | 238M |
| Cash & Short-term Investments | 32.2M | 36.6M | 23.8M | 23.6M | 38.8M | 48.4M | 23.6M | 34.2M | 47.2M | 23.1M | 19.0M |
| Total Debt | 71.5M | 62.5M | 69.5M | 93.3M | 110M | 85.3M | 87.1M | 141M | 131M | 132M | 116M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.3M | 30.0M | 12.0M | 21.3M | 31.8M | 63.5M | 10.3M | 19.4M | 48.7M | -433K | 59.4M |
| Capital Expenditure | 9.98M | 15.7M | 19.4M | 26.8M | 25.6M | 20.2M | 19.0M | 8.34M | 9.88M | 9.28M | 5.47M |
| Free Cash Flow | 6.28M | 14.3M | -7.49M | -5.58M | 6.27M | 43.2M | -8.74M | 11.1M | 38.8M | -9.71M | 54.0M |
| Ratios | |||||||||||
| ROE | 13.7% | 16.2% | 5.9% | 10.1% | 16.9% | 19.4% | 13.0% | 5.6% | 6.6% | -0.1% | 2.1% |
| ROA | 7.5% | 9.5% | 3.2% | 5.2% | 8.5% | 10.6% | 7.2% | 2.8% | 3.6% | -0.1% | 1.2% |
| Net Profit Margin | 10.5% | 12.4% | 4.8% | 7.5% | 11.7% | 13.9% | 10.6% | 5.0% | 6.2% | -0.1% | 2.2% |
| Debt to Equity | 0.50x | 0.40x | 0.46x | 0.59x | 0.64x | 0.41x | 0.39x | 0.61x | 0.54x | 0.56x | 0.49x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stratec SE dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 7.29M | 0.60 | - |
| 2024 | EUR 6.69M | 0.55 | 41.7% |
| 2023 | EUR 11.8M | 0.97 | 90.2% |
| 2022 | EUR 11.5M | 0.95 | 39.4% |
| 2021 | EUR 10.9M | 0.89 | 27.3% |
| 2020 | EUR 10.1M | 0.83 | 34.6% |
| 2019 | EUR 9.81M | 0.81 | 61.1% |
| 2018 | EUR 9.53M | 0.79 | 106.3% |
| 2017 | EUR 9.13M | 0.76 | 35.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Stratec SE
- Insiders 63.06%
- Institutions 34.49%
- Public & others 2.46%
- Shares outstanding 12.0M
- Free float 11.5M
Stratec SE company profile
- Company name
- Stratec SE
- Ticker
- 0RAR.LSE
- ISIN
- DE000STRA555
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 1,383
- Fiscal year end
- December
- Address
- Gewerbestrasse 37, Birkenfeld, Germany, 75217
- Phone
- 49 7082 7916 0
- Website
- stratec.com
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
Stratec SE management
6- Mr. Marcus WolfingerChairman of Board of Management & CEO · born 1967
- Dr. Claus VielsackDirector of Product Development & Member of Board of Management · born 1967
- Dr. Georg BauerDirector for Sales & Member of Management Board · born 1973
- Mr. Hermann LeistnerFounder & Advisor · born 1946
- Ms. Tanja BucherlCFO & Member of Management Board · born 1988
- Mr. Jan KeppelerHead of Investor Relations, Sustainability & Corporate Communications